icon-folder.gif   Conference Reports for NATAP  
 
  The Liver Meeting
San Francisco
November 2018
Back grey_arrow_rt.gif
 
 
 
Establishment of High Rates of Functional Control and Reversal of Fibrosis Following Treatment of HBeAg Negative Chronic HBV Infection with REP 2139-Mg / REP 2165-Mg, Tenofovir Disoproxil Fumarate and Pegylated Interferon Alpha-2a
 
 
  Reported by Jules Levin
AASLD Nov 2019

0225191

0225192

0225193

0225194

0225195

0225196

0225197